Core Insights - iRhythm Technologies Inc reported Q1 2025 revenue of $158.7 million, a 20.3% increase year over year, surpassing the consensus estimate of $153.38 million [1] - The adjusted EPS loss was 95 cents, an improvement from a loss of $1.23 a year ago, also beating the consensus estimate of 98 cents [1] - Gross profit reached $109.2 million, up 24.8% from $87.5 million in the same period of 2024, with a gross margin of 68.8%, an increase from 66.3% [2] Revenue and Growth - The revenue increase was primarily driven by heightened demand for Zio services [1] - iRhythm's fiscal 2025 sales guidance is projected at $690 million to $700 million, an increase from the previous guidance of $675 million to $685 million and above the consensus of $681.56 million [3] Market Expansion - The company has recently launched its Zio long-term continuous ECG monitoring system in Japan, expanding its market presence to a total of six markets outside the U.S. [3] Analyst Ratings and Price Action - Analysts have shown positive sentiment, with Wells Fargo upgrading iRhythm from Equal-Weight to Overweight and raising the price target from $104 to $130 [5] - Baird and Needham also maintained their Outperform and Buy ratings, respectively, with increased price targets [5] - Following the positive earnings report, IRTC stock rose by 19.1% to $129.37 [4]